Study of Protein and Molecular Differences in Primary and Recurrent Breast Cancer Focusing on Key Receptors and Tumor Progression

What this Trial Is About

Researchers are investigating the proteomic and molecular features of primary and recurrent or metastatic breast tumors. The study particularly focuses on the expression of S100 protein and the estrogen receptor ER, progesterone receptor PR, and HER2 genes. The aim is to deepen understanding of the molecular pathways that drive breast cancer progression and how these pathways respond to different treatments. The research also seeks to link proteomic results with survival data and to find potential blood markers that could indicate breast cancer progression. Participants will undergo standard treatment while tissue and blood samples are collected at various times. Tissue samples, both fresh frozen and formalin-fixed paraffin-embedded, will be taken during surgery or biopsy of primary or recurrentmetastatic tumors. Blood samples will be collected before neoadjuvant treatment if applicable, and before and after surgery or biopsy. For recurrent or metastatic cases without surgery, blood will be drawn before starting treatment. Additional blood samples will be taken annually for up to five years in primary cases and up to two years in recurrent or metastatic cases. Throughout the study, clinical data will be gathered alongside the biological samples to support the research. The primary outcome measure is the investigation of proteins and their pathways in primary breast cancer over ten years. Secondary outcomes include comparing molecular profiles between primary and recurrentmetastatic tumors, identifying new molecular mechanisms of recurrence, and finding potential targets for treatment. Participants will be followed and evaluated over the long term to support these research goals.

Breast Cancer Proteomics and Molecular Heterogeneity